Literature DB >> 9374373

Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer.

K A Scott1, R A Walker.   

Abstract

Cyclin E is a G1 cyclin that is essential for the transition from G1 to S phase in the cell cycle. Alterations to cyclin E expression or regulation could be important in tumorigenesis. Previous immunohistochemical and immunoblotting studies have investigated the expression of cyclin E in breast carcinomas. In this study, cyclin E has been investigated in a range of non-malignant and malignant breast using immunohistochemistry. Normal and benign tissue from pre- and post-menopausal women (39 cases), non-involved tissue from cancer-containing breasts (47 cases), ductal carcinoma in situ (22 cases) and invasive breast carcinomas (109 cases) have been examined. There was no reactivity in any of the non-malignant breast. Only one ductal carcinoma in situ contained more than 5% reactive cells. A total of 28% of invasive carcinomas had > 5% of reactive cells (range 0-88% positive cells, mean 12.59%, median 1.0%). A significant association was found with poorer differentiation (P < 0.001), high MIB1 index (P < 0.001), lack of oestrogen receptor (0.05 > P > 0.025) and the presence of p53 protein (0.05 > P > 0.025). Virtually all cases with cyclin E and p53 were poorly differentiated. The presence of cyclin E is therefore only found in breast malignancies and is associated with more aggressive features, including high proliferation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374373      PMCID: PMC2228161          DOI: 10.1038/bjc.1997.550

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

Review 1.  G1 events and regulation of cell proliferation.

Authors:  A B Pardee
Journal:  Science       Date:  1989-11-03       Impact factor: 47.728

2.  Duct carcinoma in situ. Pathology and treatment.

Authors:  M D Lagios
Journal:  Surg Clin North Am       Date:  1990-08       Impact factor: 2.741

3.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.

Authors:  J Isola; T Visakorpi; K Holli; O P Kallioniemi
Journal:  J Natl Cancer Inst       Date:  1992-07-15       Impact factor: 13.506

4.  Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle.

Authors:  A Koff; A Giordano; D Desai; K Yamashita; J W Harper; S Elledge; T Nishimoto; D O Morgan; B R Franza; J M Roberts
Journal:  Science       Date:  1992-09-18       Impact factor: 47.728

5.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

6.  Association of human cyclin E with a periodic G1-S phase protein kinase.

Authors:  V Dulić; E Lees; S I Reed
Journal:  Science       Date:  1992-09-25       Impact factor: 47.728

7.  Cyclin D1 and prognosis in human breast cancer.

Authors:  C Gillett; P Smith; W Gregory; M Richards; R Millis; G Peters; D Barnes
Journal:  Int J Cancer       Date:  1996-04-22       Impact factor: 7.396

8.  The prevalence of carcinoma in situ in normal and cancer-associated breasts.

Authors:  C E Alpers; S R Wellings
Journal:  Hum Pathol       Date:  1985-08       Impact factor: 3.466

9.  Risk factors for breast cancer in women with proliferative breast disease.

Authors:  W D Dupont; D L Page
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

10.  TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.

Authors:  S Gretarsdottir; L Tryggvadottir; J G Jonasson; H Sigurdsson; K Olafsdottir; B A Agnarsson; H Ogmundsdottir; J E Eyfjörd
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

View more
  9 in total

Review 1.  Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.

Authors:  R J Michalides
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

2.  Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance.

Authors:  N Kato; J Watanabe; T Jobo; Y Nishimura; T Fujisawa; Y Kamata; H Kuramoto
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-08       Impact factor: 4.553

3.  Specific overexpression of cyclin E·CDK2 in early preinvasive and primary breast tumors in female ACI rats induced by estrogen.

Authors:  S John Weroha; Wilma L Lingle; Yan Hong; Sara Antonia Li; Jonathan J Li
Journal:  Horm Cancer       Date:  2010-02-10       Impact factor: 3.869

Review 4.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

5.  Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms.

Authors:  D C Porter; N Zhang; C Danes; M J McGahren; R M Harwell; S Faruki; K Keyomarsi
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

6.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

7.  Cyclin E deregulation is an early event in the development of breast cancer.

Authors:  Alexandra Shaye; Aysegul Sahin; Qiang Hao; Kelly Hunt; Khandan Keyomarsi; Isabelle Bedrosian
Journal:  Breast Cancer Res Treat       Date:  2008-12-24       Impact factor: 4.872

8.  Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.

Authors:  Satu Luhtala; Synnöve Staff; Minna Tanner; Jorma Isola
Journal:  Tumour Biol       Date:  2016-01-26

Review 9.  Measuring proliferation in breast cancer: practicalities and applications.

Authors:  Mark J Beresford; George D Wilson; Andreas Makris
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.